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Abstract
Purpose Assessment of stroke risk and implementation of
appropriate antithrombotic therapy is an important issue in
atrial fibrillation patients. Current risk scores do not take into
consideration the comorbidities associated with elevated
thromboembolic like obstructive sleep apnea (OSA). The
aim of the study was to establish whether atrial fibrillation
patients with coexisting OSA have higher stroke risk accord-
ing to CHADS2 and CHA2DS2-VASc scores.
Methods Two hundred fifty-four consecutive patients hospi-
talized with a primary diagnosis of atrial fibrillation partici-
pated in the study. All patients underwent whole night
polygraphy and were scored in both CHADS2 and
CHA2DS2-VASc according to their medical records or de
novo diagnosis.
Results The study population was predominantly male
(65.4 %; mean age, 57.5±10.0 years) with a high prevalence
of hypertension (73.6 %), dyslipidemia (63.4 %), and obesity
(42.9 %). OSA was present in 47.6 % of patients, who more
often had history of stroke (p=0.0007). Stroke risk profile
assessed by both CHADS2 and CHA2DS2-VASc scores was
higher in patients with OSA (1.2±0.9 vs. 0.8±0.6; p<0.0001
and 2.2±1.7 vs. 1.5±1.1; p=0.001) than without it. Differ-
ences in the stroke risk remained significant across different
age strata, and the trend for point values in CHADS2 and
CHA2DS2-VASc scores rose along with OSA severity accord-
ing to the apnea–hypopnea index (AHI; p for trend <0.001).
Conclusions OSA was highly prevalent in atrial fibrillation
patients. Patients with OSA have higher CHADS2 and
CHA2DS2-VASc scores. Mean CHADS2 and CHA2DS2-
VASc scores rise with OSA severity. Future studies should
prospectively research on potential inclusion of OSA to stroke
prediction models.
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Introduction
Atrial fibrillation is one of the most common types of arrhyth-
mia. Currently, it occurs in approximately 2 % of the general
population, but it is estimated that its incidence will increase
even more [1, 2]. The presence of the arrhythmia is associated
with an elevated risk of cardiovascular events, most of all
stroke [3]. It is estimated that approximately one fifth of all
strokes is attributable to the atrial fibrillation and, therefore,
could be avoided if patients weremanaged properly [4]. Given
the high atrial fibrillation prevalence and disabling conse-
quences of stroke, prevention of the thromboembolic events
is currently one of the key issues in treatment of atrial fibril-
lation patients [3, 5].
Cur ren t gu ide l ines recommend plann ing the
anticoagulation treatment individually, according to the pa-
tients’ thromboembolic risk. Two tools recommended to be
used in this indication are the CHADS2 and CHA2DS2-VASc
scores. Both tools are based on easy to obtain clinical data
including the presence of congestive heart failure, age, diabe-
tes mellitus, sex, history of stroke, or vascular disease. Point
values obtained in the CHADS2 and CHA2DS2-VASc scores
give us approximate information of the annual stroke risk and,
therefore, indications for anticoagulation treatment [6, 7].
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Assessment of CHADS2 and CHA2DS2-VASc scores in obstructive
sleep apnea patients with atrial fibrillation
Unfortunately, like most point scores, CHADS2 and
CHA2DS2-VASc are likely to overlook important param-
eters, including comorbidities associated with elevated
thromboembolic risk. One of them is obstructive sleep
apnea (OSA), a sleep-disordered breathing with high
prevalence in atrial fibrillation patients (estimated to be
between 32 and 49 %) [8]. OSA is strongly associated
with hypercoagulation, which has been reported in the
literature previously [9–11]. OSA influence strongly also
on prevalence of hypertension, sympathetic dysregula-
tion, or many other cardiovascular risk factors, which
causes elevated risk of stroke and other thromboembolic
events. The strongly elevated thromboembolic risk and
mutual exacerbation of the diseases even caused that,
recently, atrial fibrillation and OSA have been postulat-
ed to be components of one clinical syndrome [12].
We hypothesize that the stroke risk will be higher in
patients with OSA and that this relationship will be
clearly shown by the results of CHADS2 and
CHA2DS2-VASc scores in both groups of patients. The
aim of the study was to determine if the occurrence of
OSA in atrial fibrillation patients is associated with




In accordance with the Declaration of Helsinki, the study
protocol was approved by the Regional Ethics Committee.
Before the study entry, a written informed consent was ob-
tained from every study participant. Two hundred fifty-four
consecutive patients hospitalized in a high-volume, tertiary
University Hospital Cardiology Department were enrolled.
The cause of admission in every patient was prequalification
for atrial fibrillation ablation procedure. Subjects were eligible
to participate in this study if they were 18 to 75 years of age
without previously diagnosed OSA or central sleep ap-
nea and no current treatment with continuous positive
airway pressure (CPAP) device. Exclusion criteria in-
cluded prior ablation for atrial fibrillation, untreated
overt hyper- or hypothyroidism (defined according to
current guidelines), myocardial infarction or decompen-
sation of heart failure within 6 months prior to study
entry, fatal condition with estimated life expectancy of
≤6 months, presence of contraindications for polygraphy
study including acute and/or chronic pulmonary diseases
like obstructive pulmonary disease or active tuberculo-
sis, neuromuscular disease, hemochromatosis, severe
neurologic, or psychiatric disorders [13, 14].
Assessment of atrial fibrillation and cardiovascular risk
Medical history of patients, including occurrence of cardio-
vascular risk factors, was taken on admission in every patient
by a qualified physician. In the night following the admission,
every patient underwent a whole night sleep study using a
portable polygraphy device for diagnosing sleep disorder
breathing (Embletta Gold; Flaga, Reykjavik, Iceland).
Diagnosis of atrial fibrillation was based on at least one
arrhythmia episode recorded in a 24-h ECGHolter monitoring
in 6 months prior to the study enrollment. Diagnosis of the
arrhythmia was determined with respect to the European
Society of Cardiology Guidelines for the management of atrial
fibrillation from 2010 and its update from 2012 [3, 5]. Patients
included in the study were prequalified for atrial fibrillation
ablation; therefore, no permanent atrial fibrillation was diag-
nosed in the study population (permanent arrhythmia is diag-
nosed only if it is decided not to pursue rhythm control
strategy). Paroxysmal atrial fibrillation was defined as self-
terminating, usually within 48 h, which may continue for up to
7 days. Persistent atrial fibrillation was defined when arrhyth-
mia episode either lasted longer than 7 days or required
termination by cardioversion either with drugs or by direct
current cardioversion [3].
All patients were interviewed for history of cardiac failure,
moderate to severe left ventricle systolic dysfunction, hyper-
tension, diabetes, stroke or transient ischemic attack (TIA),
and vascular disease (including myocardial infarction, com-
plex aortic plaque, and peripheral artery disease including
prior revascularization, amputation due to peripheral artery
disease, or its angiographic evidence). Diagnosis of the
abovementioned diseases were made basing on eligible med-
ical records, taking prescription drugs applicable for the re-
spective disease (i.e., hypoglycemic agents for diabetes) or as
a de novo diagnosis according to current criteria.
Assessment of stroke risk
The CHADS2 and CHA2DS2-VASc scores were calculated
for every patient based on predefined point systems according
to the current guidelines for scoring and diagnosing all men-
tioned conditions [6, 7]. In the CHA2DS2-VASc score, 2
points were assigned if a patient had a history of stroke
or TIA or was ≥75 years of age. One point was
assigned for the age 65–74 years, female sex, history
of hypertension, diabetes, recent cardiac failure, and
vascular disease (history of myocardial infarction, pres-
ence complex aortic plaque, or peripheral artery dis-
ease). In the CHADS2 score, 2 points are assigned for
the history of stroke or TIA, and 1 point for each of the
following: history of congestive heart failure, diabetes
or hypertension, and age ≥75 years.
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Diagnosis of OSA
Polygraphy used in the study is a level 3 sleep monitoring tool
according to the recommendations of the European Respira-
tory Society and the European Society of Hypertension [15].
This kind of devices record >4 channels including channels to
detect respiratory movements or respiratory effort, airflow,
heart rate, ECG, and oxygen saturation and are used for
objective OSA diagnosis confirmation. All polygraphy results
were scored manually according to the recommendations of
the American Academy of Sleep Medicine by a qualified
cardiologist specialized in sleep medicine [16]. Apnea was
defined as a complete cessation (residual air flow equal of
<10 % of the preceding stable breathing period) of airflow
lasting ≥10 s. Obstructive breathing event occurs with com-
plete upper airway obstruction. Hypopnea was defined as a
noticeable decrease (>30 and <90 %) in the respiratory signal
amplitude which lasted for >10 and accompanied by
desaturation (≥4 %). OSA diagnosis was made when the
apnea–hypopnea index (AHI, number of apneas and
hypopneas per hour) was ≥5 per hour. Patients with confirmed
OSA were subsequently grouped according to OSA severity
with AHI≥OSA severity was classified as mild when AHI ≥5
and <15 per hour, moderate when AHI was ≥15 and ≤30 per
hour, and as severe when AHI was >30 per hour.
Statistical analysis
Data were tested for normality using the Kolmogorov–
Smirnov test. Continuous data are presented as mean and
95 % confidence intervals (CI), with statistical comparisons
performed with the Mann–Whitney test or Student’s t test.
Categorical variable comparison was made using either the
chi-square or Fisher exact tests. A one-way analysis of vari-
ance was used to assess the impact of OSA severity according
to AHI on the CHADS2 and CHA2DS2-VASc scores. A p
value of less than 0.05 was considered statistically significant,
whereas the confidence intervals were 95 %. All statistical
calculations were performed using commercially available
SAS statistical software version 8.02 (SAS Institute, Inc.,
Cary, NC, USA).
Results
The baseline characteristics of the study population are de-
scribed in Table 1. Of the 254 patients, 88 (34.6 %) were
females. Mean age of the study population was 57.5±
10.0 years. Hypertension was present in 73.6 % of patients,
whereas 63.4 % suffered from dyslipidemia. The prevalence
of body mass index (BMI) exceeding criteria for obesity
diagnosis (>30 kg/m2) was 42.9 %. Paroxysmal atrial
fibrillation was present in the majority of patients (69.3 %),
and for the rest, persistent atrial fibrillation was diagnosed.
Mean CHADS2 and CHA2DS2-VASc scores were, respective-
ly, 1.0±0.8 and 1.8±1.4. Mean AHI value in the whole study
population was 8.4±10.8 per hour.
OSAwas present in 47.6 % of patients. Details of patients’
characteristics according to OSA status are presented in
Table 2. Patients with OSA were older (59.6±7.9 vs. 55.5±
11.3 years; p=0.008) and had higher neck (41.2±3.8 vs. 39.4
±3.3 cm; p=0.0002) and waist circumferences (108.5±13.1
vs. 108.3±89.2 cm; p<0.0001) than patients without OSA.
Obesity was diagnosed in more patients in OSA than non-
OSA group (54.5 vs. 32.3%; p=0.0006). Also, the prevalence
of other comorbidities was different in patients with and
without OSA. Patients with OSA more often were diagnosed
with hypertension (80.2 vs. 67.7 %; p=0.03), diabetes
mellitus (13.2 vs. 5.3 %; p=0.05), or had history of stroke
(13.2 vs. 1.5 %; p=0.0007) than patients without the sleep-
disordered breathing condition. The form of arrhythmia that
was predominant in OSA patients was persistent atrial fibril-
lation, whereas in patients without OSA, atrial fibrillation was
more often paroxysmal (p=0.02).
General thromboembolic risk profile assessed by both
CHADS2 and CHA2DS2-VASc scores was higher in patients
Table 1 Baseline characteristics of the study population
Parameter Value
Age (years) 57.5±10.0
Female 88 (34.6 %)
Hypertension 187 (73.6 %)
Diabetes mellitus 23 (9.1 %)
Prior stroke or TIA 18 (7.1 %)
Dyslipidemia 161 (63.4 %)
Smoking 26 (10.2 %)
SBP (mm Hg) 132.1±16.9
DBP (mm Hg) 80.9±11.1
BMI >30 kg/m2 109 (42.9 %)
Neck circumference (cm) 40.3±3.6
Waist circumference (cm) 108.4±65.7
Paroxysmal AF 176 (69.3 %)
AHI<5 per hour 133 (52.4 %)
AHI≥5 and <15 per hour 74 (29.1 %)
AHI≥15 and <30 per hour 35 (13.8 %)
AHI≥30 per hour 12 (4.7 %)
CHADS2 1.0±0.8
CHA2DS2-VASc 1.8±1.4
AHI (per hour) 8.4±10.8
Values are mean±SD or n (%),
AF atrial fibrillation, AHI apnea–hypopnea index, BMI body mass index,
DBP diastolic blood pressure, SBP systolic blood pressure, SD standard
deviation, TIA transient ischemic attack
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with OSA than without it. Mean CHADS2 score in the group
with and without OSA was 1.2±0.9 and 0.8±0.6 points,
respectively (p<0.0001). In CHA2DS2-VASc scale, patients
with OSA scored 2.2±1.7, while the mean score in non-OSA
patients was 1.5±1.1 points (p=0.001) (Fig. 1). Differences in
thromboembolic risk remained significant even when we an-
alyzed patients in different age strata. CHADS2 score in
patients ≤65 years old was higher in OSA than non-OSA
patients (0.7±0.6 vs. 1.1±0.8 points; p=0.0004), similarly to
patients >65 years of age (0.9±0.5 vs. 1.7±1.3 points; p=
0.03, respectively) (Fig. 2a). The same trend was observed in
respect to the mean CHA2DS2-VASc score. In patients
≤65 years old, the mean value in OSA patients was 1.2±0.9
and in non-OSA patients was 1.7±1.4 points (p=0.03). Anal-
ysis of the group of patients older than 65 years also showed
that OSA patients had higher (2.5±1.0 points) CHA2DS2-
VASc score than non-OSA patients (3.6±1.54 points; p=
0.004) (Fig. 2b).
In the general population, both CHADS2 and CHA2DS2-
VASc scores seemed to correspond with OSA severity. Divid-
ing the patients into four groups: non-OSA (with AHI <5 per
hour), mild OSA (AHI ≥5 and <15 per hour), moderate OSA
(AHI ≥15 and ≤30 per hour), and severe OSA (AHI >30 per
hour) showed that there was a significant trend towards a rise
in CHADS2 (p for trend <0.001) and CHA2DS2-VASc scores
(p for trend <0.001) (Fig. 3).
To perform a sensitivity analysis, we divided patients into
groups with paroxysmal and permanent atrial fibrillation. We
observed higher CHADS2 and CHA2DS2-VASc scores in all
OSA patients. In permanent atrial fibrillation patients, the
mean CHADS2 score was 0.9±0.5 vs. 1.2±0.8 (p=0.3) for
non-OSA and OSA patients, respectively, and CHA2DS2-
VASc score was 1.7±1.0 vs. 1.9±1.6 (p=0.8). In the group
with paroxysmal atrial fibrillation, the mean CHADS2was 0.7
±0.6 vs. 1.3±1.0 (p<0.0001), and the mean CHA2DS2-VASc
was 1.4±1.1 vs. 2.4±1.7 (p<0.0001) respectively.
Discussion
CHADS2 and CHA2DS2-VASc scores are simple risk assess-
ment schemes. CHADS2 was developed basing on the AF
Investigators and Stroke Prevention in Atrial Fibrillation
(SPAF) Investigators criteria and includes stroke risk factors
like recent cardiac failure, hypertension, age >75 years, dia-
betes, and history of stroke or TIA [6]. The presence of those
factors showed to be predictive for thromboembolic risk in the
population of SPAF trial [17]. In all of the SPAF trials, OSA
was not assessed and, therefore, could not be included in the
risk model. Risk assessment scheme was developed with data
from Euro Heart Survey on Atrial Fibrillation, which again
does not include data on OSA [18]. CHA2DS2-VASc score
Table 2 Patients’ characteristics
according to the presence of ob-
structive sleep apnea
Values are mean±SD or n (%)
AF atrial fibrillation, AHI apnea–
hypopnea index, BMI body mass
index, DBP diastolic blood pres-
sure, OSA obstructive sleep ap-
nea, SBP systolic blood pressure,
SD standard deviation, TIA tran-
sient ischemic attack
Parameter Patients without OSA (n=133) Patients with OSA (n=121) p value
Age (years) 55.5±11.3 59.6±7.9 0.008
Female 52 (39.1 %) 36 (29.8 %) 0.15
Hypertension 90 (67.7 %) 97 (80.2 %) 0.03
Diabetes mellitus 7 (5.3 %) 16 (13.2 %) 0.05
Prior stroke or TIA 2 (1.5 %) 16 (13.2 %) 0.0007
Dyslipidemia 84 (63.2 %) 77 (63.6 %) 0.96
Smoking 16 (12.0 %) 10 (8.3 %) 0.43
SBP (mm Hg) 131.5±17.0 132.8±16.8 0.55
DBP (mm Hg) 80.0±10.8 82.0±11.5 0.16
BMI >30 kg/m2 43 (32.3 %) 66 (54.5 %) 0.0006
Neck circumference (cm) 39.4±3.3 41.2±3.8 0.0002
Waist circumference (cm) 108.3±89.2 108.5±13.1 <0.0001
Paroxysmal AF 101 (75.9 %) 75 (62.0 %) 0.02
CHADS2 0.8±0.6 1.2±0.9 <0.0001





















Fig. 1 Mean CHADS2 and CHA2DS2-VASc scores in patients with and
without obstructive sleep apnea (OSA)
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attributes points for history of congestive heart failure, hyper-
tension, diabetes, stroke, vascular disease, age ≥75 or 65–74,
and female sex [7]. Both scores showed to predict incidence of
stroke basing on the patient’s score [6, 19]. Moreover, they
showed value in predicting other complications like pulmo-
nary embolism or coronary artery disease severity [20, 21].
Some authors even postulated that CHADS2 can be useful in
predicting ischemic stroke in patients without atrial fibrillation
[22]. Both scores are clinically useful, but there are several
disparities between them. Current guidelines encourage the
use of CHA2DS2-VASc because some analyses showed that
CHADS2 may underestimate stroke risk in patients with lower
value range [23]. Nevertheless, both schemes are not free from
flaws, and both may underestimate real stroke risk.
Meta-analyses of prospective cohort studies show that
OSA patients, similarly to atrial fibrillation patients, are more
likely to suffer from stroke [9–11, 24]. Moreover, sleep-
disordered breathing is a predictor of all-cause mortality and
recurrent vascular events following stroke [25]. In our study,
like in the previous observations, the occurrence of OSAwas
associated with older age and obesity. These two risk factors
are associated not only with the occurrence of OSA but also
the promotion of atrial fibrillation in the general population [2,
26, 27]. There is a blurred line between concepts that OSA
promotes atrial fibrillation, atrial fibrillation contributes to
OSA development, or both conditions are caused by other
common risk factors [8]. Nevertheless, cardiovascular risk,
including stroke risk, is altered additively by both diseases.
The concept of adding OSA as a stroke risk factor to the
CHADS2 has been previously proposed by Yazdan-Ashoori
and Baranchuk [28], but literature lacked evidence from trials
that were designed to support the thesis. It was proposed to
include OSA in the CHADS2 score by allocating 1 point for
OSA, and as the authors said, to rename the score CHADSS2
by adding an extra “S” for sleep apnea. The design of the
present trial also does not provide an answer if OSA is an
independent risk factor for future stroke and/or mortality in
this group of patients, but it highlights two problems. First of
all, in our study, OSA patients had higher CHADS2 and
CHA2DS2-VASc scores even irrespectively of age group. This
is caused by higher morbidity rates and worse general risk
profile in this group of patients. Second of all, OSA is a strong
stroke risk factor. Patients afflicted with OSA already are at
higher risk of stroke when we do not incorporate OSA as an
additional factor in the risk prediction model; it is possible that
we can oversee some OSA patients with low CHADS2 and
CHA2DS2-VASc scores who would benefit from
anticoagulation therapy.
The newest data show that in spite of the current guidelines,
many patients with atrial fibrillation in whom anticoagulation is





























































Fig. 2 Relationship of mean obstructive sleep apnea (OSA) with





















































Fig. 3 Trends in CHADS2 (a) and CHA2DS2-VASc (b) scores according
to obstructive sleep apnea (OSA) severity
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countries [29, 30]. In many cases, patients with atrial fibrillation
are undertreated, and many of the strokes associated with OSA
could have been avoided by proper risk assessment and more
aggressive treatment. Some authors even propose for active
screening for atrial fibrillation in all OSA patients, saying that
in this high-risk group, this kind of intervention would benefit
in stroke rate reduction [31]. OSA screening is easy and widely
applicable, while confirmation of the diagnosis with
polygraphy or polysomnography becomes more accessible.
In conclusion, OSAwas highly prevalent in atrial fibrillation
patients. Patients with OSA have higher CHADS2 and
CHA2DS2-VASc scores. Mean CHADS2 and CHA2DS2-VASc
scores rise with OSA severity assessed by AHI. OSA can be a
predictor of higher stroke risk in atrial fibrillation patients. All
atrial fibrillation patients with OSA should be monitored more
carefully for stroke risk factors and promptly introduced with
anticoagulation therapy if needed. Further studies are needed to
decide if OSA carries a risk beyond its most often comorbidities
incorporated in the CHADS2 and CHA2DS2-VASc scores and if
it should be included in the risk prediction schemes.
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